Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 138, Issue 7, Pages 1197-1203
Publisher
Springer Nature
Online
2012-03-16
DOI
10.1007/s00432-012-1183-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Personalized Medicine: The Road Ahead
- (2012) Rutika Mehta et al. Clinical Breast Cancer
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pharmacogenomic Contribution to Drug Response
- (2011) Roshawn G. Watson et al. CANCER JOURNAL
- The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies
- (2011) Z. Chen et al. MUTAGENESIS
- Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls
- (2010) Xiangyu Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
- (2010) J Bray et al. BRITISH JOURNAL OF CANCER
- The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors
- (2010) Christina Justenhoven et al. CANCER
- Personalized treatment of early-stage breast cancer: Present concepts and future directions
- (2010) Nadia Harbeck et al. CANCER TREATMENT REVIEWS
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2C19*2polymorphism is associated with increased survival in breast cancer patients using tamoxifen
- (2010) Rikje Ruiter et al. PHARMACOGENOMICS
- Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma
- (2009) Hee Nam Kim et al. AMERICAN JOURNAL OF HEMATOLOGY
- Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
- (2009) Vasiliki Michalaki et al. ANTI-CANCER DRUGS
- Association Studies of CYP1A1 and GSTM1 Polymorphisms with Esophageal Cancer Risk: Evidence-based Meta-analyses
- (2009) Wen-Lei Zhuo et al. ARCHIVES OF MEDICAL RESEARCH
- Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis
- (2009) Theodoros N. Sergentanis et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic Associations of 115 Polymorphisms with Cancers of the Upper Aerodigestive Tract across 10 European Countries: The ARCAGE Project
- (2009) C. Canova et al. CANCER RESEARCH
- Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends
- (2009) Alvaro Moreno-Aspitia et al. CLINICAL THERAPEUTICS
- Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
- (2009) Stephen Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started